Trial Profile
A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 24 Apr 2012 Additional lead trial investigator identified as reported by University Hospital Medical Information Network - Japan.
- 24 Apr 2012 Actual end date (1 Oct 2011) added as reported by University Hospital Medical Information Network - Japan.
- 24 Apr 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.